

Date: 12-04-2022

To

Dept of Corporate Services,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street Fort,
Mumbai- 400001.

Dear Sir / Madam,

Sub: Statement of Investor Complaints for the quarter ended 31st March 2022 pursuant to Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code - 526445

In compliance with the requirement under the Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the statement of Investor Complaints, for the quarter ended March 31, 2022:

S. NO	PARTICULARS	NO. OF COMPLIANTS
1.	No. of Investor complaints pending at the beginning of the Quarter	0
2.	No. of Investor complaints received during the Quarter	0
3.	No. of Investor complaints disposed of during the Quarter	0
4.	No. of Investor complaints unresolved at the end of the Quarter	0

This is for your information and records.

Thanking You,

Yours Faithfully,
For **INDRAYANI BIOTECH LIMITED**



Vennila Vijayaragavan
Company Secretary & Compliance Officer

